GTF2F1

Across TCGA pan-cancer cohorts, GTF2F1 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated GTF2F1 data layer compared with 25 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher GTF2F1 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated GTF2F1 expression acts as an unfavorable survival marker, although some lineages such as LUAD and PDAC show a favorable association.

LUAD, CCRCC, and HNSC are the cancer types where GTF2F1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Median	III,IV	1.000	0.308	.001	40	view →
CCRCC	OS	Tertile	All	0.903	1.000	.022	5	view →
HNSC	DFS	Quartile	III,IV	0.624	0.907	.013	4	view →
PDAC	DFS	Median	All	0.438	0.272	.026	4	view →
UCEC	OS	Tertile	All	1.000	0.902	.049	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

GTF2F1–LUAD (OS)

Open the LUAD breakdown →